A Dose-Escalation and Dose-Expansion Study Evaluating the Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors
Latest Information Update: 18 May 2023
At a glance
- Drugs PGV 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 14 May 2023 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
- 14 May 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.
- 14 May 2023 Status changed from not yet recruiting to recruiting.